Cargando…

Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database

BACKGROUND: The loading dose of teicoplanin (TEIC) is recommended for implementation. However, there is significant discrepancy between the dose settings in the package insert and, in the guidelines, and the actual status of loading doses in Japan is unclear. Furthermore, TEIC causes liver injury as...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Ryota, Muraki, Yuichi, Inose, Ryo, Ichii, Moeno, Sawada, Keisuke, Mizuno, Kanako, Koizumi, Ryuji, Tsuzuki, Shinya, Ishikane, Masahiro, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619217/
https://www.ncbi.nlm.nih.gov/pubmed/37908001
http://dx.doi.org/10.1186/s40780-023-00304-y
_version_ 1785129938733498368
author Goto, Ryota
Muraki, Yuichi
Inose, Ryo
Ichii, Moeno
Sawada, Keisuke
Mizuno, Kanako
Koizumi, Ryuji
Tsuzuki, Shinya
Ishikane, Masahiro
Ohmagari, Norio
author_facet Goto, Ryota
Muraki, Yuichi
Inose, Ryo
Ichii, Moeno
Sawada, Keisuke
Mizuno, Kanako
Koizumi, Ryuji
Tsuzuki, Shinya
Ishikane, Masahiro
Ohmagari, Norio
author_sort Goto, Ryota
collection PubMed
description BACKGROUND: The loading dose of teicoplanin (TEIC) is recommended for implementation. However, there is significant discrepancy between the dose settings in the package insert and, in the guidelines, and the actual status of loading doses in Japan is unclear. Furthermore, TEIC causes liver injury as side effect. Although the risk of developing liver injury has not been reported to be increased following a loading dose based on the guidelines, there is a lack of reports in large populations. Therefore, we evaluated the trend in the loading dose and factors affecting the efficacy and safety of TEIC administration. METHODS: A Japanese administrative claims database was used in this study. Trends in loading doses were evaluated in target populations administered TEIC between 2010 and 2019. Patient characteristics were adjusted by propensity score matching based on the guideline group (total dose of 3 days > 1,600 mg) and non-guideline group (≤ 1,600 mg) of the loading dose. Finally, univariable and multivariable conditional logistic regression analysis was performed to evaluate factors affecting 30-day mortality and liver injury. RESULTS: A total of 10,030 patients were selected based on these criteria. The proportion of loading doses based on the recommended guidelines showed an increase over time, regardless of the implementation of therapeutic drug monitoring (TDM), but especially so in cases where TDM was implemented, the loading doses were administered in accordance with the recommendations of the guidelines. Conditional logistic regression analysis showed a relationship between drug management and guidance fees (odds ratio [OR]: 0.45, 95% confidence interval [CI]: 0.36‒0.55), a reimbursement indicating pharmacist intervention, and a reduction in 30-day mortality. In addition, loading doses based on the recommended guidelines had no influence on liver injury, and other factors were not significantly associated with increased incidence of liver injury. CONCLUSION: Thus, this study implies the benefits of pharmacological management as indicated by drug management and guidance fee and supports the implementation of loading doses based on the guideline on TEIC administration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-023-00304-y.
format Online
Article
Text
id pubmed-10619217
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106192172023-11-02 Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database Goto, Ryota Muraki, Yuichi Inose, Ryo Ichii, Moeno Sawada, Keisuke Mizuno, Kanako Koizumi, Ryuji Tsuzuki, Shinya Ishikane, Masahiro Ohmagari, Norio J Pharm Health Care Sci Research Article BACKGROUND: The loading dose of teicoplanin (TEIC) is recommended for implementation. However, there is significant discrepancy between the dose settings in the package insert and, in the guidelines, and the actual status of loading doses in Japan is unclear. Furthermore, TEIC causes liver injury as side effect. Although the risk of developing liver injury has not been reported to be increased following a loading dose based on the guidelines, there is a lack of reports in large populations. Therefore, we evaluated the trend in the loading dose and factors affecting the efficacy and safety of TEIC administration. METHODS: A Japanese administrative claims database was used in this study. Trends in loading doses were evaluated in target populations administered TEIC between 2010 and 2019. Patient characteristics were adjusted by propensity score matching based on the guideline group (total dose of 3 days > 1,600 mg) and non-guideline group (≤ 1,600 mg) of the loading dose. Finally, univariable and multivariable conditional logistic regression analysis was performed to evaluate factors affecting 30-day mortality and liver injury. RESULTS: A total of 10,030 patients were selected based on these criteria. The proportion of loading doses based on the recommended guidelines showed an increase over time, regardless of the implementation of therapeutic drug monitoring (TDM), but especially so in cases where TDM was implemented, the loading doses were administered in accordance with the recommendations of the guidelines. Conditional logistic regression analysis showed a relationship between drug management and guidance fees (odds ratio [OR]: 0.45, 95% confidence interval [CI]: 0.36‒0.55), a reimbursement indicating pharmacist intervention, and a reduction in 30-day mortality. In addition, loading doses based on the recommended guidelines had no influence on liver injury, and other factors were not significantly associated with increased incidence of liver injury. CONCLUSION: Thus, this study implies the benefits of pharmacological management as indicated by drug management and guidance fee and supports the implementation of loading doses based on the guideline on TEIC administration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-023-00304-y. BioMed Central 2023-11-01 /pmc/articles/PMC10619217/ /pubmed/37908001 http://dx.doi.org/10.1186/s40780-023-00304-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Goto, Ryota
Muraki, Yuichi
Inose, Ryo
Ichii, Moeno
Sawada, Keisuke
Mizuno, Kanako
Koizumi, Ryuji
Tsuzuki, Shinya
Ishikane, Masahiro
Ohmagari, Norio
Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title_full Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title_fullStr Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title_full_unstemmed Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title_short Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database
title_sort trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a japanese administrative claims database
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619217/
https://www.ncbi.nlm.nih.gov/pubmed/37908001
http://dx.doi.org/10.1186/s40780-023-00304-y
work_keys_str_mv AT gotoryota trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT murakiyuichi trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT inoseryo trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT ichiimoeno trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT sawadakeisuke trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT mizunokanako trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT koizumiryuji trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT tsuzukishinya trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT ishikanemasahiro trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase
AT ohmagarinorio trendsinteicoplaninloadingdoseimplementationfrom2010to2019andevaluationofsafetyandefficacyfactorsaretrospectivecohortstudybasedonajapaneseadministrativeclaimsdatabase